America Great Health
Market Movers (8-K)
OTC.Pink
America Great Health announced the resignation of its Chief Financial Officer, Quinn Chen, effective June 30, 2025, with CEO Mike Wang assuming interim duties.
OTC.Pink
America Great Health has signed a framework agreement with Xinjiang Wuse to distribute its ion peptide products in China.
OTC.Pink
8-K: America Great Health Enters Strategic Partnership with Aide Huhuan to Expand into Chinese Market
America Great Health has partnered with Aide Huhuan to distribute its ion peptide products in China, leveraging Aide Huhuan's market reach and distribution network.
OTC.Pink
America Great Health's subsidiary has secured a contract with a Chinese company to develop technology for a sea cucumber ion peptide project using its patented protein modification technology.
OTC.Pink
8-K: America Great Health Subsidiary Enters Technology Contract for Cancer Cell Inhibition Development
America Great Health's subsidiary, International Institute of Great Health, has secured a contract with Yunan Yunchi Xiai Trading Co. Ltd. to develop cancer cell inhibiting technology using its patented protein modification process.
OTC.Pink
8-K: America Great Health Enters Strategic Partnership with Aide Huhuan to Expand into Chinese Market
America Great Health has signed a Framework Agreement with Aide Huhuan to distribute its ion peptide products in China.
Quarterly Earnings (10-Q)
OTC.Pink
America Great Health's Q3 2025 report shows increased sales due to new product launches, but the company still faces substantial doubt about its ability to continue as a going concern due to recurring net losses and a significant shareholders' deficit.
Capital raise
Worse than expected
OTC.Pink
America Great Health's Q2 2025 report shows increased sales due to new product launches, but the company still faces net losses and substantial doubt about its ability to continue as a going concern.
Capital raise
Worse than expected
OTC.Pink
America Great Health's Q1 2025 shows increased sales due to new product launches, but the company still faces a significant shareholders' deficit and going concern uncertainties.
Capital raise
Worse than expected
OTC.Pink
America Great Health saw a significant increase in sales during the third quarter of 2024, but ongoing losses and a substantial shareholders' deficit raise concerns about the company's ability to continue as a going concern.
Worse than expected
Capital raise
OTC.Pink
10-Q: America Great Health Reports Increased Sales but Continues to Face Losses in Latest Quarterly Filing
America Great Health's latest quarterly report shows increased sales driven by new products, but the company continues to operate at a loss and faces going concern challenges.
Worse than expected
Capital raise
OTC.Pink
America Great Health has filed an amended quarterly report on Form 10-Q/A for the period ended September 30, 2023, to include updated certifications and explanations regarding its financial results.
Worse than expected
Delay expected
Capital raise
Annual Reports (10-K)
OTC.Pink
America Great Health (AAGH) has filed its annual report for the fiscal year ended June 30, 2025, detailing operational results, financial condition, and forward-looking statements, while acknowledging substantial doubt about its ability to continue as a going concern.
Worse than expected
Capital raise
OTC.Pink
America Great Health's 10-K filing reveals increased sales revenue for fiscal year 2024, but also a larger net loss due to rising operating expenses and cost of goods sold, alongside ongoing concerns about the company's ability to continue as a going concern.
Worse than expected
Capital raise
OTC.Pink
America Great Health files an amendment to its annual report, showcasing increased sales and reduced losses for the fiscal year ended June 30, 2023.
Better than expected
Capital raise